Ignite Creation Date:
2024-05-05 @ 5:27 PM
Last Modification Date:
2024-10-26 @ 9:32 AM
Study NCT ID:
NCT00460486
Status:
COMPLETED
Last Update Posted:
2023-04-19
First Post:
2007-04-13
Brief Title:
Immunogenicity and Safety Study of FSME-IMMUN 05 mL in Adult Subjects Previously Vaccinated According to a Rapid Immunization Schedule
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
Open-Label Phase 3b Clinical Study to Evaluate the Immunogenicity and Safety of FSME-IMMUN 05 ml With the First and Second Vaccination Being Administered According to a Rapid Immunization Schedule in Healthy Adults Aged 16 Years or Older
Status:
COMPLETED
Status Verified Date:
2023-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objective of this study is to investigate the immunogenicity and safety of FSME-IMMUN 05 ml in two age strata stratum A 16 to 49 years stratum B 50 years with the first and second vaccinations being administered according to a rapid immunization schedule 12 2 days apart The third vaccination will be administered approximately 6 months after the first dose
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None